• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025

    2/10/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Gross Profit Increased 23.5% from the Previous Year to $7.7 million

    Gross Margins Increased to 18.5%, up from 15.0% the Previous Year

    Revenue Increased 0.3% Year-Over-Year to $41.8 Million

    LOS ANGELES, Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024.

    Fiscal Second Quarter 2025 Financial Results

    • Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.
    • Gross profit of $7.7 million, an increase of 23.5% compared to $6.3 million in the fiscal second quarter of 2024.
    • Gross margin of 18.5%, an increase of 23% compared to 15.0% second quarter of fiscal 2024.
    • Total operating expenses of $15.1 million, an increase of 48.0% as compared to $10.2 million for second quarter of fiscal 2024.
    • Net loss of ($8.0) million, compared to net loss of ($4.0) million in the second quarter of fiscal 2024.

    "Despite challenging macroeconomic conditions, we had strong results for the quarter given the strategic advances we made in becoming a leading global innovative vaping technology and precision dosing solutions company," said Michael Wang, Co-Chief Executive Officer of Ispire. "This is particularly evident as we further expanded into international markets. Our BrkFst brand recently launched in Africa, marking our first international nicotine license arrangement and product launch. The BrkFst brand has seen early success as we have quickly established a presence in over 500 retail locations across South Africa and Nigeria, including major chains like Pick n Pay and Forecourts. We've implemented a sweeping market activation strategy with brand ambassadors conducting daily events in major metropolitan areas, which has been instrumental in building strong relationships with both retailers and consumers. We now plan to accelerate our expansion strategy to reach more than 2,000 stores in the next six months through additional strategic partnerships."

    "Furthermore, our IKE Tech joint venture's component PMTA strategy represents a groundbreaking opportunity. We've completed a successful pre-PMTA meeting with the FDA, who indicated they would accept our component PMTA submission and consider our priority review. The legal U.S. market for electronic nicotine delivery systems is approximately $11 billion, with an additional $7 billion potential in alternative markets. This is a significant opportunity for our potentially industry changing blockchain-based age verification technology which could help prevent youth access," Mr. Wang concluded.

    Jim McCormick, Chief Financial Officer of Ispire, added, "Our financial performance this quarter demonstrates our ability to execute on our strategic priorities for growth and financial management. The authorization by the Board of up to a $10 million stock repurchase program underscores our confidence in Ispire's long-term potential and our commitment to creating value for shareholders. In Malaysia, we've made significant regulatory progress, obtaining critical nicotine import and export licenses and preparing for our manufacturer's license, which we expect will enable us to scale our operations to 70 production lines in our new facility. Also, subsequent to quarter end, the Company moved certain daily roles and functions to our Malaysian operations to help further streamline our overall business and to reduce operating expenses by an anticipated $8 million annually. This balanced approach allows us to simultaneously invest in our growth strategies and return value to our shareholders, which we believe positions us for continued success in the evolving global nicotine product market."

    Financial Results for the Fiscal Second Quarter Ended December 31, 2024

    Ispire reported revenue of $41.8 million for the fiscal second quarter ended December 31, 2024, compared to $41.7 million for the prior comparable period, an increase of $0.1 million. The growth in revenue is largely due to the increase in contribution of sales from expansion overseas.

    Gross profit for the second quarter of fiscal 2025, was $7.7 million compared to $6.3 million in the year-ago period. Gross margin increased to 18.5% from 15.0% in the second quarter of fiscal 2024. The increase in gross profit and gross margin was primarily due to changes in product mix with more higher margin products being sold during the three months ended December 31, 2024.

    Total operating expenses for the second fiscal quarter of 2025 were $15.1 million, compared to $10.2 million for second fiscal quarter of 2024. The increase in operating expenses was primarily due to increased expenses associated with our increased revenue generation, continued investment in Malaysia, and increased expenses related to our product development function.

    Net loss was $8.0 million or ($0.14) per share for the fiscal second quarter of 2025, versus a net loss of $4.0 million, or ($0.07) per share for the fiscal second quarter of 2024.

    At December 31, 2024, Ispire had a cash position of $34.4 million, as well as working capital of $6.1 million.

    Conference Call

    The Company will conduct a conference call at 8:00am Eastern Time on Monday, February 10, 2025, to discuss the results. Ispire management will host the conference call, followed by a question-and-answer period.

    Please call the conference call dial-in 5-10 minutes prior to the start time and ask for the "Ispire Technology Call." An operator will register your name and organization.

    • Date: Monday, February 10, 2025
    • Time: 8:00am ET
    • Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

    This conference call will be broadcast live on the Internet and can be accessed by all interested parties at   https://viavid.webcasts.com/starthere.jsp?ei=1705094&tp_key=6946006674. 

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available from 11:00 am ET on February 10, 2025, through February 24, 2025. To listen, please dial +1 844-512-2921 or +1 412-317-6671. Use the passcode 13751256 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 200 patents received or filed globally. Ispire's tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company's cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company's website, any other website or any social media, is not a part of this press release.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (In $USD, except share and per share data)







    December 31,

    2024





    June 30,

    2024



    Assets













    Current assets:













    Cash



    $

    34,372,851





    $

    35,071,294



    Restricted cash





    22,535







    -



    Accounts receivable, net





    67,700,463







    59,734,765



    Inventories, net





    7,900,110







    6,365,394



    Prepaid expenses and other current assets





    2,324,245







    1,400,152



    Total current assets





    112,320,204







    102,571,605



    Non-current assets:

















    Property, plant and equipment, net





    2,365,115







    2,582,457



    Intangible assets, net





    2,120,367







    1,375,666



    Right-of-use assets – operating leases





    2,949,756







    3,579,140



    Other investment





    2,000,000







    2,000,000



    Equity method investment





    10,071,380







    10,248,048



    Other non-current assets





    215,612







    284,050



    Total non-current assets





    19,722,230







    20,069,361



    Total assets



    $

    132,042,434





    $

    122,640,966



    Liabilities and stockholders' equity

















    Current liabilities

















    Accounts payable



    $

    5,156,302





    $

    3,779,723



    Accounts payable – related party





    86,375,645







    67,046,472



    Contract liabilities





    1,882,743







    2,218,166



    Accrued liabilities and other payables





    11,576,021







    11,738,339



    Operating lease liabilities – current portion





    1,245,061







    1,207,832



    Total current liabilities





    106,235,772







    85,990,532





















    Non-current liabilities:

















    Operating lease liabilities – net of current portion





    1,572,574







    2,194,094



    Total liabilities





    107,808,346







    88,184,626





















    Commitments and contingencies



































    Stockholders' equity:

















    Common stock, par value $0.0001 per share; 140,000,000 shares authorized;

    56,677,982 and 56,470,636 shares issued and outstanding as of December 31,

    2024 and June 30, 2024





    5,668







    5,647



    Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no

    shares issued at December 31, 2024 and June 30, 2024





    -







    -



    Additional paid-in capital





    46,670,244







    43,217,391



    Accumulated deficit





    (22,418,700)







    (8,825,041)



    Accumulated other comprehensive (loss) income





    (23,124)







    58,343



    Total stockholders' equity





    24,234,088







    34,456,340



    Total liabilities and stockholders' equity



    $

    132,042,434





    $

    122,640,966



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In $USD, except share and per share data)







    Three Months Ended

    December 31,





    Six Months Ended

    December 31,







    2024





    2023





    2024





    2023





























    Revenue



    $

    41,827,860





    $

    41,685,561





    $

    81,166,173





    $

    84,550,208





































    Cost of revenue





    34,105,289







    35,432,663







    65,769,224







    71,452,462





































    Gross profit





    7,722,571







    6,252,898







    15,396,949







    13,097,746





































    Operating expenses:

































    Sales and marketing expenses





    2,061,664







    1,394,407







    5,053,911







    2,419,626



    General and administrative expenses





    13,020,962







    8,778,715







    22,965,962







    15,476,589





































    Total Operating expenses





    15,082,626







    10,173,122







    28,019,873







    17,896,215





































    Loss from operations





    (7,360,055)







    (3,920,224)







    (12,622,924)







    (4,798,469)





































    Other income (expense):

































    Interest income, net





    59,755







    203,101







    59,841







    275,347



    Exchange gain (loss), net





    (245,173)







    30,856







    (127,588)







    34,517



    Other income (expense), net





    6,861







    46,535







    13,796







    3,331





































    Total Other income (expense), net





    (178,557)







    280,492







    (53,951)







    313,195





































    Loss before income taxes





    (7,538,612)







    (3,639,732)







    (12,676,875)







    (4,485,274)





































    Income taxes - current





    (460,031)







    (352,180)







    (916,784)







    (848,225)





































    Net loss



    $

    (7,998,643)





    $

    (3,991,912)





    $

    (13,593,659)





    $

    (5,333,499)





































    Other comprehensive loss

































    Foreign currency translation adjustments





    73,470







    114,327







    (81,467)







    158,790



    Comprehensive income (loss)



    $

    (7,925,173)





    $

    (3,877,585)





    $

    (13,675,126)





    $

    (5,174,709)





































    Net loss per share

































    Basic and diluted



    $

    (0.14)





    $

    (0.07)





    $

    (0.24)





    $

    (0.10)





































    Weighted average shares outstanding:

































    Basic and diluted





    56,658,012







    54,270,236







    56,629,666







    54,258,224



     

    For more information, kindly contact:

    IR Contacts:

    Investor Relations

    Sherry Zheng

    718-213-7386

    [email protected]

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570-209-2947

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-second-quarter-2025-302371600.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Financials

    Live finance-specific insights

    See more
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

      LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

      5/7/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. to Participate in Webull Corporate Webinar Series on February 18, 2025

      LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Michael Wang, Co-Chief Executive Officer, will present at the Webull Consumer Webinar Series: Consumer, on February 18, 2025. Conference Details: Webull Corporate Webinar Series - ConsumerDate/Time: Tuesday, February 18th at approximately 3:00 p.m. ETPresenter: Michael Wang, Co-CEORegistration Link: HERERecent Highlights: 2/10/25: Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 1/22/25: Ispire Technology Inc. Announces Stock Repurchase Program 1/15/25: Ispi

      2/12/25 8:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ispire Technology with a new price target

      ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

      5/20/24 7:18:59 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    SEC Filings

    See more

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ISPR
    Leadership Updates

    Live Leadership Updates

    See more

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/23/25 4:30:34 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/15/25 4:30:11 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/12/25 7:00:13 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Approval of Interim License for Manufacturing of Nicotine Products in Malaysia

      Interim License Approved in May, with Authority to Begin Manufacturing of Nicotine Products in Malaysia Immediately LOS ANGELES, May 22, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced it has received the interim license from the Malaysian Government for the manufacturing of nicotine products. This is the first and only nicotine manufacturing license issued in Malaysia approved by both the Federal and State authorities and cements Ispire's position as the only company with full authorization for export, import, and production. The approval of the interim license

      5/22/25 9:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Key Leadership Appointments

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

      8/14/23 8:35:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • CLO and Secretary Pryzbyla Steven P. sold $1,785 worth of shares (500 units at $3.57), decreasing direct ownership by 0.12% to 416,710 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/19/25 4:30:15 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • CLO and Secretary Pryzbyla Steven P. sold $24,982 worth of shares (6,200 units at $4.03), decreasing direct ownership by 1% to 417,210 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/14/25 4:30:05 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cox Brent was granted 8,077 shares, increasing direct ownership by 63% to 20,998 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      1/10/25 6:05:19 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Ispire Technology Inc.

      SC 13G - Ispire Technology Inc. (0001948455) (Subject)

      7/12/24 5:00:02 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care